Table 4.
Cohort characteristics for overall patient cohort and age-determined cohorts in PD-1 inhibitor monotherapy subgroup
| Overall N (%) (n=374) |
<65 years N (%) (n=146) |
65–74 years N (%) (n=127) | ≥75 years N (%) (n=101) | X2 | ||||||
| All grade | ≥G3 | All grade | ≥G3 | All grade | ≥G3 | All grade | ≥G3 | All grade | ≥G3 | |
| All toxicity | 203 (54.3) | 35 (9.4) | 76 (52.1) | 13 (8.9) | 74 (58.3) | 16 (12.6) | 54 (53.5) | 6 (5.9) | NS | NS |
| Adverse event | ||||||||||
| Dermatitis | 77 (20.6) | 2 (0.5) | 25 (17.1) | 0 (0.0) | 24 (18.9) | 0 (0.0) | 28 (27.7) | 2 (2.0) | NS | NS |
| Lower GI | 46 (12.3) | 9 (2.4) | 14 (9.6) | 6 (4.1) | 18 (14.2) | 2 (1.6) | 14 (13.9) | 1 (1.0) | NS | NS |
| Endocrine | 71 (19.0) | 8 (2.1) | 36 (24.7) | 3 (2.1) | 24 (18.9) | 4 (3.1) | 11 (10.9) | 1 (1.0) | 0.007 | NS |
| Hepatitis | 34 (9.1) | 5 (1.3) | 17 (11.6) | 0 (0.0) | 12 (9.4) | 4 (3.1) | 5 (5.0) | 1 (1.0) | NS | NS |
| Rheumatological | 15 (4.0) | 2 (0.5) | 3 (2.1) | 0 (0.0) | 7 (5.5) | 2 (1.6) | 5 (5.0) | 0 (0.0) | NS | NA |
| Other | 60 (16.0) | 12 (3.2) | 23 (15.7) | 4 (2.7) | 26 (20.5) | 7 (5.5) | 11 (10.9) | 1 (1.0) | NS | NS |
|
Overall N (%) (n=243) |
<65 years N (%) (n=81) |
65–74 years N (%) (n=88) |
≥75 years N (%) (n=74) |
X2 | ||||||
| Median no of cycles | 7 (1–60) | 5 (1–60) | 7 (1–49) | 8 (1–33) | NA | |||||
| Discontinuation due to toxicity | 14 (5.8) | 7 (8.6) | 5 (5.7) | 2 (2.7) | NS | |||||
A total of 374 patients overall for which toxicity data are known, 243 patients for which continuation/discontinuation data are known.
GI, gastrointestinal; NA, Insufficient patient numbers for analysis; NS, not significant.